Published: 24 April 2024
Author(s): Yuji Nishimoto, Yugo Yamashita, Takeshi Morimoto, Ryuki Chatani, Kazuhisa Kaneda, Nobutaka Ikeda, Yohei Kobayashi, Satoshi Ikeda, Kitae Kim, Moriaki Inoko, Toru Takase, Yukihito Sato, Tetsuya Watanabe, Takahisa Yamada, Masatake Fukunami, Takeshi Kimura, COMMAND VTE Registry-2 Investigators
Section: Original Article

Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), constitutes the second leading cause of morbidity and mortality in patients with cancer besides the progression of cancer itself [1]. In addition, the incidence of cancer-associated VTE has increased over time mainly because of an improved prognosis of cancer, increased usage of anticancer-drugs with a potential higher risk of thrombosis, and increased detection by frequent imaging examinations for cancer assessment [2–4].

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.